Valuation: Immunovia AB

Market Cap 43.39M 4.35M 3.86M 3.61M 3.27M 6.18M 419M 6.23M 16.88M 214M 16.32M 15.97M 687M P/E 2026 *
-0.65x
P/E 2027 * -1.61x
Enterprise Value 8.39M 841K 746K 698K 633K 1.2M 81.03M 1.2M 3.26M 41.34M 3.16M 3.09M 133M EV / Sales 2026 *
2.62x
EV / Sales 2027 * 0.77x
Free-Float
90.23%
Yield 2026 *
-
Yield 2027 * -
1 day-36.61%
1 week-36.61%
1 month-24.30%
3 months-49.69%
6 months-47.64%
Current year-57.97%
1 month 0.1
Extreme 0.0975
0.32
Current year 0.1
Extreme 0.0975
0.32
1 year 0.1
Extreme 0.0975
0.35
3 years 0.1
Extreme 0.0975
2.78
5 years 0.1
Extreme 0.0975
131.5
10 years 0.1
Extreme 0.0975
292
Manager TitleAgeSince
Chief Executive Officer 53 2023-04-28
Chief Tech/Sci/R&D Officer 55 2024-04-28
Chief Tech/Sci/R&D Officer 54 2024-01-30
Director TitleAgeSince
Director/Board Member 72 2016-12-08
Chairman 70 2023-05-25
Director/Board Member 51 2020-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-32.03%-36.61% - - 4.76M
-2.98%-3.24%+20.85%+31.84% 250B
-2.53%-5.16%+0.29%-0.58% 156B
-0.42%-2.42%-10.52%+39.53% 144B
-0.50%-4.35%-56.65%-18.36% 61.45B
-0.86%-0.40%+12.21%+19.78% 50.28B
+1.66%-1.55%-20.09%-20.26% 46.73B
-1.00%-3.36%+19.55%+53.45% 48.29B
+0.02%+1.26%-4.31%+40.76% 45.89B
-0.84%-1.47%+32.90%+64.08% 43.24B
Average -4.17%-2.32%-0.64%+23.36% 93.91B
Weighted average by Cap. -1.22%-2.77%+2.50%+23.30%

Financials

2026 *2027 *
Net sales 3.2M 321K 285K 266K 241K 456K 30.92M 459K 1.24M 15.77M 1.2M 1.18M 50.7M 17.3M 1.73M 1.54M 1.44M 1.31M 2.47M 167M 2.48M 6.73M 85.27M 6.51M 6.37M 274M
Net income -87M -8.72M -7.74M -7.24M -6.57M -12.4M -841M -12.49M -33.84M -429M -32.73M -32.03M -1.38B -76M -7.62M -6.76M -6.33M -5.74M -10.83M -734M -10.91M -29.56M -375M -28.59M -27.98M -1.2B
Net Debt -35M -3.51M -3.11M -2.91M -2.64M -4.99M -338M -5.02M -13.61M -173M -13.17M -12.89M -555M -30M -3.01M -2.67M -2.5M -2.26M -4.28M -290M -4.31M -11.67M -148M -11.29M -11.04M -475M
Projected Income Statement - Annual - Immunovia AB
Logo Immunovia AB
Immunovia AB (publ) is a Sweden-based diagnostic company that is developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s test platform called IMMray. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.
Employees
18
Date Price Change Volume

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Immunovia AB